Here's why the Polynovo (ASX:PNV) share price is rocketing 12% today

The company's shares are taking off on Tuesday.

| More on:
A drawing of a white rocket streaking up, indicating a surging share pirce movement

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Polynovo Ltd (ASX: PNV) share price is racing ahead today following a positive business update from the company.

At the time of writing, the medical device company's shares are fetching for $1.53, up 12.50%. This means that its shares have clawed back the consecutive losses registered in the past week.

What did Polynovo announce?

In a statement to the ASX, Polynovo advised that its United States segment has experienced a strong start to the second quarter.

Sales for October and November have recorded a 133% increase to $4.66 million over the prior corresponding period ($1.99 million). The business noted that last month was particularly solid, equalling the record month of sales in July 2021.

The United States portfolio added 11 additional accounts since 30 September, bringing to the total to 146 accounts.

Across the United Kingdom, Ireland and Europe, Polynovo acknowledged the region has underperformed to expectations. A number of initiatives are being undertaken to improve the sales base along with its distributor network.

In Australia and New Zealand, the segment remains on track despite a temporary blip in the reduction of burn cases. Polynovo highlighted that more than 40% of all BTM use is now outside of burns.

Furthermore, an undisclosed number of large corporations have expressed their interest in bringing BTM to their retrospective markets. Polynovo stated that it is working to establish these relationships for FY22.

The company has also stepped up its recruitment drive as well as its international search for a new CEO. The board is confident of filling the position sometime within the first quarter of 2022.

Polynovo chair, David Williams commented:

There has been a significant uplift in intensity in all areas of the business in the last month. We are adding immediately significant scale to our US salesforce and some important new hires in the UK and other parts of the business.

Polynovo share price snapshot

Over the past 12 months, the Polynovo share price has continued its downward trend to post a 65% loss.

In comparison, the S&P/ASX 200 Healthcare (ASX: XHJ) sector has gained around 7.3% in the same time frame.

It's worth noting that Polynovo shares hit a multi-year low of $1.35 yesterday. This is a huge difference from when its shares were trading above the $4 mark in December 2020.

Based on today's price, Polynovo presides a market capitalisation of about $912.72 million and has approximately 661.39 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Man looking happy and excited as he looks at his mobile phone.
Healthcare Shares

Guess which ASX healthcare stock is jumping 7% on big news

This stock is getting a lot of attention from investors on Wednesday. But why?

Read more »

Four smiling young medics with arms crossed stand outside a hospital.
Healthcare Shares

How much further upside is there for Mesoblast shares after soaring 23% in a month?

Could FDA approval send this healthcare stock towards further gains?

Read more »

woman in lab coat conducting testing representing biotech
Healthcare Shares

Is this soaring ASX 200 healthcare share just getting started?

If its lead therapy gets US approval, the stock can continue to climb.

Read more »

A happy elderly woman smiles and cheers as she looks at good investment news on her laptop.
Broker Notes

Macquarie forecasts this $3.4 billon ASX healthcare share is set surge 33%

Macquarie tips material outperformance from this ASX healthcare share in 2026.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Own CSL shares? Here are the key dates for 2026

It's been a bad year for CSL shares. What's ahead in 2026?

Read more »

A graphic of a pink rocket taking off above an increasing chart.
Healthcare Shares

Guess which ASX 300 healthcare share is rocketing 28% on global expansion news

Investors are piling into the ASX 300 healthcare share on Tuesday. Let’s see why.

Read more »

A man in a business suit scratches his head looking at a graph that started high then dips, then starts to go up again like a rollercoaster.
Healthcare Shares

Is Sigma Healthcare share a healthy buy, after hitting new lows?

The Chemist Warehouse merger and ageing population might boost this stock's appeal.

Read more »

A sad looking scientist sitting and upset about a share price fall.
Healthcare Shares

Telix shares fall despite 'significant milestone'

Let's see what the biotech has announced on Monday.

Read more »